1.1Allyl ether cleavage
A palladium(0) complex cleaves the allyl ether through formation of a palladium–allyl intermediate. A barbiturate anion captures the allyl fragment, and protonation releases the hydroxyl.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A palladium(0) complex cleaves the allyl ether through formation of a palladium–allyl intermediate. A barbiturate anion captures the allyl fragment, and protonation releases the hydroxyl.
Tetrabutylammonium fluoride in tetrahydrofuran cleaves the silicon–oxygen bond. A short exposure at low temperature limits acetate migration, and an aqueous workup protonates the liberated alkoxide.
Hydrogen adsorbs on the nickel surface and supplies hydrogen for cleavage of the benzylic carbon–oxygen bond. The reaction yields the free hydroxyl and toluene, and filtration removes the nickel.
The silyl ether remains on the terminal hydroxyl during neutral palladium-catalyzed hydrogenolysis of the benzyl ether. A separate fluoride treatment releases the terminal hydroxyl when it is needed for coupling.
The terminal hydroxyl bears a chloroacetyl ester, while the hydroxyl being released bears a benzyl ether. Thiourea removes the chloroacetyl ester after the benzyl cleavage step under conditions that retain ordinary acetate esters.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
An analytical laboratory prepares a reference material from the benzyl-protected, two-branched N-acetyl-D-galactosamine intermediate by hydrogenolysis with palladium and hydrogen. After removing the catalyst, the laboratory isolates the debenzylated compound by preparative liquid chromatography and assigns its concentration by quantitative nuclear magnetic resonance. Separate injections of the starting intermediate and the isolated product establish retention times for monitoring benzyl removal.
Palladium supported on neutral alumina replaces palladium on carbon in a stirred slurry reactor. The reactor suspends the catalyst in a solution of the protected intermediate and supplies hydrogen through the headspace. Liquid chromatography tracks the benzyl-protected starting material and the 4,4′-dimethoxytrityl-protected product before the alumina-supported catalyst is removed by filtration.
Ammonium formate replaces externally supplied hydrogen in a stirred vessel containing the protected intermediate and a palladium catalyst. The vessel receives the formate as a metered solution while stirring keeps the catalyst suspended, and a vent carries gas from donor decomposition to the exhaust. Liquid chromatography measures benzyl removal and retention of the 4,4′-dimethoxytrityl group before the catalyst is filtered out and dissolved formate is removed during aqueous workup.
Six stirred 10 mL pressure vessels each hold 2 mL of a 25 mM solution of the protected intermediate and a palladium catalyst. Three vessels operate at 2 bar absolute hydrogen pressure and three operate at 4 bar absolute, all at 25 °C. Each vessel supplies a filtered sample at 60 minutes for chromatographic measurement of starting material, debenzylated product, and loss of the 4,4′-dimethoxytrityl group.
A stirred hydrogenolysis reactor connects to a closed pressure filter through a slurry transfer line. At the end of the reaction, the reactor vents hydrogen to a dedicated exhaust, switches to nitrogen, and transfers the slurry to the filter under nitrogen pressure. A solvent wash displaces product solution retained in the catalyst cake, and the wash joins the filtrate in a sealed receiver.
An automated sampling valve draws liquid through a catalyst-retaining frit and sends a diluted sample to a liquid chromatograph every 10 minutes. The controller compares the residual starting-material concentration and the level of trityl-loss impurity with preset limits using calibrated peak responses. When both measurements meet their limits, the controller closes the hydrogen feed and begins the programmed depressurization and nitrogen purge.
Near-ultraviolet irradiation at about 365 nm cleaves the substituted ether and releases the hydroxyl. A thin flow cell limits the optical path through the reaction solution, and chromatography removes the aromatic photoproduct.
A slurry of palladium on activated carbon supplies the catalyst for benzyl ether hydrogenolysis. Filtration through a filter aid removes the supported catalyst from the product solution.
A stirred vessel feeds hydrogen gas into the suspension of the protected carbohydrate and palladium catalyst. The reaction consumes hydrogen as it converts the benzyl ether into the free hydroxyl and toluene.
Ethyl acetate serves as the reaction solvent for the protected carbohydrate and the liquid phase of the catalyst slurry. The solvent stays neutral during hydrogenation to limit acid-promoted cleavage of the dimethoxytrityl ether.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The preparation method of claim 11, wherein in method 1, the deacetylation reaction comprises the following steps: in a solvent, a reduction reaction is carried out with compound 1-d, boron trifluoride etherate and triethylsilane to afford compound 1-e;A · US 9,914,724 B2 · claim 12
A mixture of compound (34) (0.95 g, 2.17 mmol), 4,4′-dimethoxytrityl chloride (1.10 g, 3.25 mmol), and anhydrous pyridine (12 mL) was stirred at ambient temperature for 18 hours.B · US 2022/0119424 A1 · ¶ 264
An empty cell means only that no passage was reproduced there.
The technical problem to be solved by the present invention is to provide a kind of C- aryl glycoside derivatives, and its stereoisomers, prodrugs, pharmaceutical accept salts thereof with an excellent inhibitory effect on SGLT, and the pharmaceutical compositions containing the same, the preparation methods and uses thereof.A · US 9,914,724 B2 · ¶ 6
Therefore, the re-absorption of glucose can be specifically reduced by inhibiting SGLT-2's activity in the kidney resulting in excretion of excessive glucose in the urine without body weight increase or hypoglycemia.A · US 9,914,724 B2 · ¶ 4
This disclosure pertains to oligonucleotide-quencher conjugates with improved fluorescence characteristics, and to reagents suitable for incorporating novel quencher moieties into oligonucleotides.B · US 2022/0119424 A1 · ¶ 2
The disclosure also pertains to the use of oligonucleotide-quencher conjugates in detection methods for nucleic acid targets.B · US 2022/0119424 A1 · ¶ 2
patent.fyi, US 2026/0356873 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356873/, SHA-256 f437c1511dddc273207d256c817ae2403114ccb9821026c6bbc619962851a59d